

Announcement

Mar Cor Purification Announces Health Canada License for Heat Disinfectable Portable RO for Dialysis

...New product supports patients with reliable, high quality water while reducing chemicals and labour by over 90%

Plymouth, MN (October 17, 2011)-Mar Cor Purification announced that it has received a Medical Device Class 3 license from Health Canada for a hot water disinfectable RO system for dialysis applications. The RO system can be marketed and sold in Canada for use in home dialysis and hospital clinics. The system, branded the Millenium HX (MHX), performs an automated heat disinfection on a regular schedule, providing patients with reliable, high quality water while reducing chemicals and labour by over 90%.

The MHX produces a reliable supply of water for haemodialysis that meets the standards of CAN/CSA-ISO 13959-11 and equipment standards of CAN/CSA-ISO 26722-11. The water system supports single patient dialysis and is compatible with any kidney machine on the market.

Key benefits of the MHX include variable demand production of water, an automatic disinfection feature that maintains the system in a clean state with minimal involvement from the patient or provider, quiet operation for home or nocturnal use and easy to use touch screen panel. The MHX significantly reduces the amount of labour required to disinfect the device while increasing disinfection frequency and efficacy. Mar Cor has an extensive sales and service network throughout Canada to provide service and spare parts for the MHX and other lines of water purification equipment.

According to John Rickert, Vice President Sales at Mar Cor, “The MHX represents the latest system design to control bacteria and endotoxin levels in dialysis water. Data indicates that higher water quality results in better dialysis treatment and a healthier patient. Hot water disinfection provides superior bacteria control and uses significantly less labour compared to chemical disinfection procedures.”

About Mar Cor Purification

Mar Cor Purification, a wholly-owned subsidiary of Cantel Medical Corp. (NYSE:CMN), has service offices in 22 cities in the United States and Canada, with seven ion exchange resin regeneration plants strategically located in Atlanta, Boston, Chicago, Philadelphia, San Antonio, Montreal and Toronto. The Mar Cor Life Science Group has been serving the water purification marketplace for over 35 years and has over 1,000 installations in North America in demanding applications such as pharmaceutical, food and beverage, and dialysis. It has one of the largest

Mar Cor Purification, 14550 28th Avenue North, Plymouth, MN 55447

water treatment-related technical and field service networks to support our installed systems. We offer support with design engineering capabilities, 24/7 service coverage, field application sales, experienced service technicians, and a fleet of stocked service vehicles. Mar Cor Purification is dedicated to providing innovative solutions through filtration, water, and disinfection technologies. Visit our website at <http://www.mcpur.com>.

About Cantel Medical

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for the dental industry, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. For further information, visit the Cantel website at <http://www.cantelmedical.com>.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

SOURCE: Mar Cor Purification

Contact information:

Christopher Fournier
cfournier@mcpur.com
Vice President Marketing
Mar Cor Purification
Phone: 978-453-9600